Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
SM88 is a 4-component combination consists of tyrosine isomers and 3 low dose repurposed drugs including Cyp3a4 inducer, mTOR inhibitor, and oxidative stress modulator, which may selectively kill tumor cells (J Clin Oncol 35, 2017 (suppl; abstr e14061)).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|SM88||SM-88|Racemetyrosine|Racemetirosine||SM88 is a modified tyrosine derivative that may interfere with protein synthesis, leading to oxidative damage and cell death in tumor cells (PMID: 31358523, PMID: 30929156).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||prostate cancer||not applicable||SM88||Phase II||Actionable||In a Phase II trial, SM-88 treatment resulted in stable (4/10) or rising (5/10) testosterone levels, and none of the toxicity commonly associated with androgen deprivation therapy in patients with non-metastatic recurrent prostate cancer (J Clin Oncol 36, 2018 (suppl 6S; abstr 175); NCT02796898).||detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02796898||Phase Ib/II||SM88||Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer||Completed|